Journal of Medical Microbiology, Journal Year: 2025, Volume and Issue: 74(1)
Published: Jan. 7, 2025
Introduction. Lamivudine plus dolutegravir (3TC/DTG) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) regimens are commonly used as first-line treatments for people living with human immunodeficiency virus (HIV) (PLWH) worldwide.Gap Statement. There limited comparative data on the antiviral activity safety between these in ART-naive PLWH, particularly China, where 3TC/DTG regimen was integrated into therapy 2021 gained broader adoption after its inclusion National Health Insurance 2022.Aims. This study aims to provide real-world evidence comparing B/F/TAF PLWH China.Methodology. retrospective enrolled initiating ART either or Shanghai from January 2020 2023. Demographic characteristics clinical information were collected compared each patient.Results. A total of 380 eligible, included, 190 patients group group. Following initiation ART, most (94.1 89.3% groups, respectively) achieved viral suppression (<50 copies HIV RNA per millilitre) at week 24. The CD4 cell count significantly increased a baseline 301.3±185.8 cells microlitre 479.5±229.3 36 289.2±188.8 487.8±234.2 Both groups experienced an increase blood lipid levels higher high-density lipoprotein cholesterol (HDL-C) observed Renal hepatic function indicators remained stable both groups.Conclusions. demonstrates similar efficacy does not impact liver kidney functions. Patients receiving showed plasma HDL-C those B/F/TAF, which confer long-term benefits reducing cardiovascular risk.
Language: Английский
Citations
0Prevalence of Metabolic-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes with and without HIV: Retrospective Multicenter Study
Published: Feb. 20, 2025
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a frequent complication in patients with Type 2 Diabetes (T2D). This study aims to evaluate the impact of HIV status on prevalence MASLD T2D. Methods: We utilized TriNetX global federated health research network perform comparative analysis two cohorts: T2D (Cohort 1) and without 2). Propensity score matching controlled for confounders such as age, gender, Hemoglobin A1c, LDL, HDL, total cholesterol, triglycerides, BMI, hypertension. The was exempt from IRB review it did not involve direct human subjects, per University at Buffalo Institutional Review Board. Results: Initial data included 168,428 Cohort 1 9,040,558 2. After matching, each cohort consisted 166,803 patients. 7.1% HIV-positive 6.7% HIV-negative patients, significant risk difference (RD = 0.004, 95% CI: 0.002 0.006, p < 0.0001). ratio (RR) 1.062 (95% 1.036 1.089), odds (OR) 1.067 1.039 1.096). Conclusion: exhibit slightly higher developing than their counterparts. These results underscore need specialized screening management T2D, particularly those living HIV.
Language: Английский
Citations
0Rilpivirine Ionic Liquid Nanoemulsion Augments the Oral Bioavailability of Rilpivirine and Its Delivery to the HIV Sanctuary Sites
ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown
Published: May 20, 2025
Rilpivirine (RPV) is a potent antiretroviral drug used for the long-term management of HIV infection. The high crystallinity and very low aqueous solubility RPV are responsible highly variable pharmacokinetics seen in HIV-infected patients. While fatty meals can increase absorption RPV, lipid precludes development oral lipid-based formulations such as self-nanoemulsifying systems (SNES). To improve delivery we evaluated potential six biocompatible bulky anions to transform into amphiphilic ionic liquids with only sodium docusate successfully yielded an liquid (IL), (RPV-Doc). Spectroscopic, chromatographic, thermal characterization techniques confirmed formation RPV-Doc IL. showed remarkably higher (∼100-200-fold) lipids compared pure RPV. was incorporated two SNES that, depending upon composition formulation, <100 or <250 nm nanoemulsion irrespective pH dilution medium. Oral biodistribution studies mice that both containing rapid significantly bioavailability (∼6-fold Cmax AUC) suspension. Furthermore, suspension, resulted sustained levels sanctuary sites mesenteric lymph nodes brain. Taken together, our innovative approach be tissue penetration which eventually result reduction pharmacokinetic variability therapeutic dose leading optimal utilization.
Language: Английский
Citations
0Hepatic Toxicity Assessment in HIV’s Interaction with Reverse Transcriptase and Integrase Strand Transfer Inhibitors at a Military Hospital, Southsouth Nigeria
medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown
Published: May 1, 2024
Abstract Introduction The use of Anti-retroviral therapy (ART) has made HIV a manageable condition, but there are risks associated with medications like Reverse Transcriptase Inhibitors (RTIs) and Integrase Strand Transfer (INSTIs), such as liver renal toxicity. It is essential to understand these for effective treatment case management. Investigating toxicity related RTIs INSTIs in Nigeria crucial optimizing treatment. This study aimed assess the impact Tenofovir Lamivudine Dolutegravir (TLD) on function patients at Nigerian Navy Hospital (NNH) Warri. Methods 170 participants was assessed, 120 ART remainder being HIV-negative attendees NNH used cross-sectional design selected through random sampling. We collected data using semi-structured questionnaire. Blood samples were taken venipuncture stored –20°C before analysis. Ethical approval obtained, analysis conducted SPSS Statistical Software Version 23, significance set p < 0.05. Results found significant differences AST, TP, Alb, GST levels between HIV-positive subjects receiving TLD individuals. had lower AST Alb higher TP levels. Further revealed correlations age, gender, enzymes, highlighting complex relationship HIV, function, outcomes. Conclusion suggests that decreased may have protective effect, while ALT activity minimal impact. Changes GSTs emphasize importance monitoring hepatic synthetic detoxification pathways taking TLD.
Language: Английский
Citations
1Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction
Antiviral Research, Journal Year: 2024, Volume and Issue: unknown, P. 106020 - 106020
Published: Oct. 1, 2024
Language: Английский
Citations
1Hepatic toxicity assessment in HIV’s interaction with reverse transcriptase and integrase strand transfer inhibitors at a military hospital, southsouth Nigeria
Egyptian Liver Journal, Journal Year: 2024, Volume and Issue: 14(1)
Published: Oct. 23, 2024
Abstract Introduction The use of anti-retroviral therapy (ART) has made HIV a manageable condition, but there are risks associated with medications like reverse transcriptase inhibitors (RTIs) and integrase strand transfer (INSTIs), such as liver renal toxicity. It is essential to understand these for effective treatment case management. Investigating toxicity related RTIs INSTIs in Nigeria crucial optimizing treatment. This study aimed assess the impact tenofovir lamivudine dolutegravir (TLD) on function patients at Nigerian Navy Hospital (NNH)-Warri. Methods 170 participants was assessed, 120 ART remainder being HIV-negative attendees NNH-Warri. used cross-sectional design selected through random sampling. We collected data using semi-structured questionnaire. Blood samples were taken venipuncture stored – 20 °C before analysis. Ethical approval obtained, analysis conducted SPSS Statistical Software Version 23, significance set p < 0.05. Results found significant differences AST, TP, Alb, GST levels between HIV-positive subjects receiving TLD individuals. had lower AST Alb higher TP levels. Further revealed correlations age, gender, enzymes, highlighting complex relationship HIV, function, outcomes. Conclusion suggests that decreased may have protective effect, while ALT activity minimal impact. Changes GSTs emphasize importance monitoring hepatic synthetic detoxification pathways taking TLD.
Language: Английский
Citations
1The Impact of Antiretroviral Therapy on Liver Function Among Pregnant Women Living with HIV in Co-Existence with and Without Pre-Eclampsia
Viruses, Journal Year: 2024, Volume and Issue: 17(1), P. 28 - 28
Published: Dec. 28, 2024
Pregnant women living with HIV (PWLWHIV) are at an increased risk of developing obstetrics complications such as pre-eclampsia (PE). Antiretroviral therapy (ART) remains the standard treatment for PWLWHIV and non-pregnant women. However, its use has been associated adverse liver conditions, particularly hepatotoxicity, often marked by elevated enzymes (LEEs) demonstrated aspartate transferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) in on ART. Morever, there is limited evidence about effect ART function among PE. Therefore, this review examines pathogenesis PE impact without With gathered review, it still unclear whether dysfunctions co-existence orwithout result from infection or administration exacerbated presence Among those PE, was increase enzymes, a decrease, no other studies ART-treated compared to control group. Additionally, due contradicting results. The notable trend that nevirapine reduced dysfunction more needed area, especially endemic regions, understand exact cause population. This knowledge crucial improving management PWLWHIV.
Language: Английский
Citations
1Evaluating Hepatotoxicity: A Comparative Analysis of New Generation versus Historical Antiretroviral Agents
Infectious Disease Reports, Journal Year: 2024, Volume and Issue: 16(3), P. 423 - 434
Published: April 24, 2024
(1) Background: Since the advent of zidovudine in 1987, antiretroviral therapy has undergone significant evolution, marked by introduction 34 drugs and 24 fixed-dose combinations. Despite these advances, hepatotoxicity remains a formidable challenge, influencing morbidity, mortality, treatment adherence HIV-infected patients. This study aims to compare hepatotoxic effects latest-generation medications with those older-generation therapies, assessing their long-term impact on liver health HIV (2) Methods: retrospective analyzed data from 304 patients treated either or over four years. Patients were monitored for through function tests at diagnosis, six months, one-year post-treatment initiation. (3) Results: Initial six-month showed no differences between two groups. However, post-treatment, antiretrovirals exhibited improvements ALT, AST, ALP levels, suggesting better safety profile regarding hepatotoxicity. Additionally, significantly lower incidence splenomegaly was observed newer medications. (4) Conclusions: The findings suggest that may offer safer terms compared older potential benefits health. underscores importance continuous monitoring further research optimize ART strategies, ensuring improved patient outcomes quality life individuals living HIV.
Language: Английский
Citations
0Comparative Metabolic Effects of Integrase Inhibitor and Emtricitabine-Containing Tenofovir Derivatives in People Living with HIV: A Multi-Center Retrospective Analysis
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 9, 2024
Language: Английский
Citations
0Impact of tenofovir, lamivudine, and dolutegravir on liver function in HIV-positive individuals in Southern Nigeria
Yādgār., Journal Year: 2024, Volume and Issue: 8(2), P. 28 - 33
Published: July 1, 2024
Language: Английский
Citations
0